# Retatrutide References — Full Citation Index

> Full bibliography of retatrutide citations used on this site. Every study cited with DOI and PubMed URL. Investigational compound research digest.

Every citation indexed with DOI and PubMed URL.

## Primary clinical trials

The Phase 1b, Phase 2, and Phase 3 registration sources for retatrutide. Full citations in the reference index below.

## Review literature and pharmacology

Structural biology, pharmacological reviews, 2024–2025 literature syntheses, and the systematic obesity drug pipeline review.

## References

[1] Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. https://pubmed.ncbi.nlm.nih.gov/37366315/
[2] Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. Lancet. 2023;402(10401):529-544. https://pubmed.ncbi.nlm.nih.gov/37385280/
[3] Li W, Zhou Q, Cong Z, Yuan Q, Li W, Zhao F, Xu HE, Zhao LH, Yang D, Wang MW. Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. Cell Discovery. 2024;10:77. https://pmc.ncbi.nlm.nih.gov/articles/PMC11255275/
[4] Urva S, Coskun T, Loh MT, Du Y, Thomas MK, Gurbuz S, Haupt A, Benson CT, Hernandez-Illas M, D'Alessio DA, Milicevic Z. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400:1869-1881. https://pubmed.ncbi.nlm.nih.gov/36354040/
[5] Sanyal AJ, Kaplan LM, Frias JP, Brouwers B, Wu Q, Thomas MK, Harris C, Schloot NC, Du Y, Mather KJ, Haupt A, Hartman ML. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. 2024;30:2037-2048. https://pmc.ncbi.nlm.nih.gov/articles/PMC11271400/
[6] Katsi V, Koutsopoulos G, Fragoulis C, Dimitriadis K, Tsioufis K. Retatrutide — A Game Changer in Obesity Pharmacotherapy. Biomolecules. 2025;15:796. https://pmc.ncbi.nlm.nih.gov/articles/PMC12190491/
[7] Kokkorakis M, et al. Emerging pharmacotherapies for obesity: A systematic review. Pharmacological Reviews. 2025. https://doi.org/10.1124/pharmrev.123.001045
[8] Kommu S, et al. The Effect of Triple-Hormone-Receptor Agonist Retatrutide, a Novel Medication for Weight Loss, on Cardiovascular Risk Factors. J Am Coll Cardiol. 2024. https://doi.org/10.1016/S0735-1097(24)03870-1
[9] Eli Lilly and Company. A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3). ClinicalTrials.gov NCT05882045. 2023. https://clinicaltrials.gov/study/NCT05882045
[10] Eli Lilly and Company. The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Function. ClinicalTrials.gov NCT06383390. 2024. https://clinicaltrials.gov/study/NCT06383390
[11] et al. Triple Agonism Based Therapies for Obesity. Curr Atheroscler Rep. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12304053/
[12] Bailey CJ, et al. Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities. Peptides. 2025. https://doi.org/10.1016/j.peptides.2025.171380
[13] Laroche ML, et al. Dysesthesia associated with GLP-1 agonist therapies: data-mining analysis and literature review. European Journal of Clinical Pharmacology. 2026. https://doi.org/10.1007/s00228-026-04079-7
[14] et al. The First Triple Agonist for Antiobesity: Retatrutide. Clin Diabetes. 2024. https://pubmed.ncbi.nlm.nih.gov/39724554/

---

A spec-sheet digest of the published retatrutide trial record — figures logged to their studies, gaps left visible, no clinic and no prescription.